Cancer

Title
A Comparison of Comparing the Effects, Good and/or Bad, of a Standard Lymph Node Removal Versus an Extended Lymph Node Removal for Participants with Bladder Cancer.
Trial Number
203934101911
Number of Participants
620
Principal Investigator

Marcus Quek

M.D., FACS
Urology
Associate Professor
Eligibility

Participants must have histologically proven (T2, T3, or T4a) urothelial carcinoma of the bladder (UCB) that requires primary radical cystectomy for definitive treatment. Participants must not have clinical stage consistent with a low-risk of node metastasis (CIS only, T1). Patients with a T4b (fixed lesion) are not eligible for this study. There must be plans for a cystectomy and lymph node dissection (LND) within 28 calendar days following registration. Laparoscopic surgery is not allowed. Please see the protocol for additional requirements.

Purpose

The purpose of this study is to compare the effects, good and/or bad, of performing a standard lymph node removal versus an extended lymph node removal.

Enrollment

(708) 327-5098

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.